By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Helsinn Therapeutics (US) Inc. 

1160 US Highway 22
Suite 104
Bridgewater  New Jersey  08807  U.S.A.
Phone: 908-203-6549 Fax: 908-231-1459


Helsinn is a privately owned, self-financing pharmaceutical group with headquarters in Lugano, Switzerland and subsidiaries in Ireland and the USA. The Helsinn Group has been built on the basis of a licensing of pharmaceuticals, with the recent addition of medical devices in therapeutic niche areas. Helsinn is an important player in Cancer Supportive Care and sells its products through unique business model that is focused on the in- and out- distributors in 87 countries worldwide.

Helsinn Therapeutics (U.S.), Inc. was established in January, 2009 and is currently developing clinical and preclinical stage ghrelin receptor agonists and antagonists in cancer and gastrointestinal supportive care. The company’s vision is to become a leading specialty company focused on supportive care with direct sales in the U.S. market.

Key Statistics

Ownership: Subsidiary

Web Site: Helsinn Therapeutics (US) Inc.
Employees: 40


Company News
Helsinn Therapeutics (US) Inc. And PatientsLikeMe Announce Results Of NSCLC Patient Survey On Weight Loss 9/9/2016 10:17:43 AM
Helsinn Therapeutics (US) Inc. And Eisai Inc. (ESALF.PK) Announce Revised U.S. Collaboration For CINV Franchise 3/18/2016 6:22:09 AM
Helsinn Release: Data Presented At The International Society Of Paediatric Oncology (SIOP) Congress Show Palonosetron Is A Valuable Option For Treating Pediatric Patients Receiving Moderately To Highly Emetogenic Chemotherapy 10/23/2014 12:48:09 PM
Helsinn Therapeutics (US) Inc. Strengthens Its Board Of Directors 6/25/2014 8:23:28 AM
Helsinn Therapeutics (US) Inc. Initiates Extension Study in Late-Stage Anamorelin Clinical Program for Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 12/7/2011 10:42:46 AM
Helsinn Therapeutics (US) Inc. Initiates Global Pivotal Phase III Clinical Program to Evaluate Anamorelin in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 8/23/2011 9:30:40 AM
Helsinn Therapeutics (US) Inc. Anounces New CEO, William Mann 9/9/2009 7:10:02 AM
Helsinn Healthcare SA Announces the Acquisition of Sapphire Therapeutics, Inc. to Establish Helsinn Therapeutics (US) Inc. 1/28/2009 11:27:12 AM